R. Langley

发表

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

J. Saurat, J. Ortonne, L. Dubertret, 2007, The British journal of dermatology.

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

B. Strober, A. Gottlieb, K. Papp, 2012, The British journal of dermatology.

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

B. Strober, K. Papp, R. Langley, 2013, CPT: Pharmacometrics & Systems Pharmacology.

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis

A. Menter, G. Cameron, G. Krueger, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

A. Armstrong, F. Kolbinger, K. Reich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Patient‐reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial

A. Finlay, C. Griffiths, G. Krueger, 2005, The British journal of dermatology.

Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

M. Lebwohl, K. Reich, M. Song, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

M. Song, Y. Wasfi, T. Tsai, 2018, The British journal of dermatology.

Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

M. Lebwohl, K. Reich, Y. Wasfi, 2015, The British journal of dermatology.

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

A. Gottlieb, K. Papp, K. Reich, 2016, The British journal of dermatology.

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials

K. Reich, R. Langley, R. Langley, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study

B. Strober, A. Menter, K. Papp, 2012, The British journal of dermatology.

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

M. Lebwohl, K. Papp, K. Gordon, 2021, The British journal of dermatology.

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3)

D. Shrom, A. Menter, K. Reich, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries

B. Strober, A. Menter, K. Gordon, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

B. Strober, H. Valdez, K. Papp, 2013, The British journal of dermatology.

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

K. Reich, P. Foley, K. Gordon, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle‐controlled trial

P. Schlievert, R. Langley, D. Leung, 2009, The British journal of dermatology.

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

Y. Poulin, R. Langley, R. Langley, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus

J. Saurat, K. Reich, R. Langley, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

M. Lebwohl, C. Griffiths, K. Reich, 2011, The British journal of dermatology.

Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study

K. Papp, B. Sigurgeirsson, R. Langley, 2013, The British journal of dermatology.

Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study

J. Saurat, E. Sasso, K. Reich, 2011, The British journal of dermatology.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial†

Kelly N. Taylor, Constance M. Brown, B. Elewski, 2019, The British journal of dermatology.

Matching‐adjusted indirect comparison of efficacy in patients with moderate‐to‐severe plaque psoriasis treated with ixekizumab vs. secukinumab

R. Warren, K. See, A. Nast, 2018, The British journal of dermatology.

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

A. Gottlieb, H. Nakagawa, K. Papp, 2015, The British journal of dermatology.

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate‐to‐severe plaque psoriasis

A. Armstrong, K. Reich, A. Blauvelt, 2017, The British journal of dermatology.

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

J. Ortonne, K. Papp, R. Langley, 2011, The British journal of dermatology.

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

B. Strober, A. Gottlieb, K. Papp, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

R. Langley, R. Langley, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

The interpretation of long‐term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials

K. Reich, R. Langley, R. Langley, 2013 .

Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

K. Reich, J. Szepietowski, A. Blauvelt, 2017, The British journal of dermatology.

Increased expression of IL‐17A and limited involvement of IL‐23 in patients with palmo‐plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial

R. Bissonnette, C. Lynde, R. Langley, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Exploring new concepts in the successful management of psoriasis

R. Langley, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.